SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,453 | $5,590 | $10,008 | $8,253 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Cost of Goods Sold | $580 | $1,179 | $2,408 | $2,452 |
| Gross Profit | $1,873 | $4,411 | $7,600 | $5,800 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| R&D Expenses | $0 | $2,638 | $2,555 | $1,736 |
| G&A Expenses | $151 | $130 | $122 | $1,337 |
| SG&A Expenses | $2,371 | $2,584 | $3,081 | $2,979 |
| Sales & Mktg Exp. | $692 | $937 | $1,481 | $1,643 |
| Other Operating Expenses | $3,379 | $0 | -$54 | $5 |
| Operating Expenses | $5,750 | $5,223 | $5,636 | $4,784 |
| Operating Income | -$3,877 | -$812 | $1,964 | $1,016 |
| % Margin | -158.1% | -14.5% | 19.6% | 12.3% |
| Other Income/Exp. Net | $70 | -$384 | $143 | -$15 |
| Pre-Tax Income | -$3,807 | -$1,195 | $2,106 | $1,001 |
| Tax Expense | $27 | $767 | $927 | -$1,031 |
| Net Income | -$3,833 | -$1,963 | $1,179 | $2,032 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS | -84.06 | -49.19 | 30.2 | 53.04 |
| % Growth | -70.9% | -262.9% | -43.1% | – |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| Weighted Avg Shares Out | 46 | 40 | 39 | 38 |
| Weighted Avg Shares Out Dil | 46 | 40 | 40 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $11 | $0 | $0 |
| Interest Expense | $20 | $11 | $0 | $2 |
| Depreciation & Amortization | $98 | $96 | $98 | $94 |
| EBITDA | -$3,779 | -$716 | $2,062 | $1,110 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |